The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient
Open accessAbstract
VP1 sequences were determined for poliovirus type 1 isolates obtained over a 189-day period from a poliomyelitis patient with common variable immunodeficiency syndrome (a defect in antibody formation). The isolate from the first sample, taken 11 days after onset of paralysis, contained two poliovirus populations, differing from the Sabin 1 vaccine strain by ∼10%, differing from diverse type 1 wild polioviruses by 19 to 24%, and differing from each other by 5.5% of nucleotides. Specimens taken after day 11 appeared to contain only one major poliovirus population. Evolution of VP1 sequences at synonymous third-codon positions occurred at an overall rate of ∼3.4% per year over the 189-day period. Assuming this rate to be constant throughout the period of infection, the infection was calculated to have started ∼9.3 years earlier. This estimate is about the time (6.9 years earlier) the patient received his last oral poliovirus vaccine dose, approximately 2 years before the diagnosis of immunodeficiency. These findings may have important implications for the strategy to eliminate poliovirus immunization after global polio eradication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The persistence of these viruses in immunocompromised individuals may compromise polio eradication efforts.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [107]
In the citing paper
“Recent reports describing highly divergent VDPVs associated with chronic poliovirus infections (10, 69, 88, 90, 113, 123, 216, 223) or with polio outbreaks (84, 169, 177, 226) underscored the earlier concerns and challenged the critical assumption that OPV-derived viruses would not long persist in the community.”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Most RNA viruses have highly mutable genomes that are potentially capable of rapid evolution, many of orders of magnitude faster than the genomes of DNA viruses or cellular organisms (41, 45), and polioviruses are among the most rapidly evolving of all RNA viruses (60, 88, 108, 117, 185, 226).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Nucleotide substitutions ( > 80% of which in the coding region are to synonymous codons) accumulate at an overall rate of ∼ 1% per year at all sites, and at ∼ 3% per year at synonymous sites (10, 60, 85, 88, 108, 117).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“They also appear to be largely independent of immune selection, as evolution rates are similar during prolonged replication in immunodeficient patients (10, 88, 117, 223) and during widespread circulation (60, 84, 85, 108).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Other CVID patients developed paralysis several years after receipt of the implicated OPV dose (typically the last dose) (10, 88, 223).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Symptoms of immunodeficiency typically become evident later in life, usually in the second and third decades, even though prolonged poliovirus infections may have begun years before the diagnosis of CVID (10, 88, 223).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“the neutralizing antigenic sites of iVDPV isolates are frequently highly divergent and variable, and immunodeficient prolonged excretors may be infected with more than one antigenic variant”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [88]
In the citing paper
“Some iVDPV isolates are highly divergent (∼90% VP1 sequence identity to the parental OPV strain), suggesting that the chronic poliovirus infections had persisted for 10 years or more (25, 68).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“In the rapidly evolving poliovirus genome (16, 25, 32, 35), variable sites (which represent ∼33% of total VP1 nucleotides, primarily at positions of codon degeneracy) saturate within ∼30 years.”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“Such sequence relationships are typical among isolates of locally circulating wild polioviruses (32, 55) and cVDPVs (22) but not among OPV-like or iVDPV isolates from different patients, which generally follow independent pathways of divergence from the vaccine strain (22, 25, 35; R. Park, unpublished results).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
In the citing paper
“The VP1 evolution rate estimated from the slope of the regression line was (2.47 ± 0.69) × 10−2 substitutions per synonymous site per year, approximately 80% of the rate observed for circulating wild type 1 polioviruses (16, 25, 32).”
From Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993 (2003) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kimura, M. (1980) · Journal of Molecular Evolution · doi:10.1007/bf01731581 · Cited by 29,778
PHYLIP-Phylogeny inference package (Version 3.2)
Felsenstein, J. (1989) · Cladistics · Cited by 17,682
The rapid generation of mutation data matrices from protein sequences
Jones, D. T., Taylor, W. R., & Thornton, J. M. (1992) · Computer applications in the biosciences · doi:10.1093/bioinformatics/8.3.275 · Cited by 7,003
RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL
Domingo, E., & Holland, J. J. (1997) · Annual Review of Microbiology · doi:10.1146/annurev.micro.51.1.151 · Cited by 1,514
Three-Dimensional Structure of Poliovirus at 2.9 Å Resolution
Hogle, J. M., Chow, M., & Filman, D. J. (1985) · Science · doi:10.1126/science.2994218 · Cited by 1,267
Holtzman, D. J., Powell‐Griner, E., Bolen, J. C., & Rhodes, L. (2000) · PubMed · Cited by 1,110
The Primary Immunodeficiencies
Rosen, F. S., Cooper, M. D., & WEDGWOOD, R. J. P. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408023110506 · Cited by 1,097
Chronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 450
Lederman, H. M., & Winkelstein, J. A. (1985) · Medicine · doi:10.1097/00005792-198505000-00001 · Cited by 411
Geographic distribution of wild poliovirus type 1 genotypes
Rico-Hesse, R., Pallansch, M. A., Nottay, B. K., & Kew, O. M. (1987) · Virology · doi:10.1016/0042-6822(87)90001-8 · Cited by 327
Self-citation
Research works printed but not linked: 2
- Más Lago P. Louzará C. Beltrán J. Jacobo M. Palomera R. Circulación de poliovirus en la población infantil de Cuba.Bol. Oficina Sanit. Panam.871975443449
- Sutter R. W. Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons.Infect. Med.111994426438
Cited by
Sorted by citations
Virology, epidemiology, pathogenesis, and control of enterovirus 71
Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M. J., McMinn, P. C., & Ooi, M. H. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70194-8 · Cited by 1,301
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationMolecular Epidemiology and Evolution of Enterovirus 71 Strains Isolated from 1970 to 1998
Brown, B. A., Oberste, M. S., Alexander, J. P., Kennett, M., & Pallansch, M. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.9969-9975.1999 · Cited by 431
Self-citationFrom Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed
Nathanson, N., & Kew, O. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq320 · Cited by 412
Self-citationRobinson, C. M., Jesudhasan, P. R. R., & Pfeiffer, J. K. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2013.12.004 · Cited by 312
Metadata
- Authors
- Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A.
- Affiliations
- National Center for Infectious Diseases (US)
- <!--label omitted: 2-->Divisions of Eradication of Vaccine-Preventable Diseases2 and
- Centers for Disease Control and Prevention (US)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 1998-10
- Volume
- 36
- Issue
- 10
- Pages
- 2893-2899
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC105084
- OpenAlex
- W2159041114
- Cited by
- 213
- References
- 36
- Citations by year
- 2024: 4 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 9 · 2016: 4 · 2015: 3 · 2014: 16 · 2013: 6 · 2012: 14
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliovirus type 1, vaccine-derived poliovirus, common variable immunodeficiency, viral evolution, poliomyelitis, oral polio vaccine, polio eradication
- MeSH terms
- Adult, Amino Acid Sequence, Base Sequence, Capsid, Child, Feces, Follow-Up Studies, Humans, Immunologic Deficiency Syndromes, Male, Molecular Sequence Data, Phylogeny, Viral Plaque Assay, Poliomyelitis, Poliovirus Vaccine, Oral, RNA, Viral, Genetic Variation, Virus Replication, Polymerase Chain Reaction, Sequence Alignment, Sequence Homology, Amino Acid, Poliovirus, Evolution, Molecular, Capsid Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
